Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 10/1/1997


1.		Phase III Randomized, Double-Blind Study of 5-FU/SMS 201-995 pa LAR vs 5-FU/Placebo for Unresectable Stage II or Stage III/IV Pancreatic Cancer (Summary Last Modified 10/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				SANDOZ-SMSM-304-E-00 NCI-V95-0798

Last Modified: 12/1/1998


2.		Phase III Randomized Double-Blind Study of Tamoxifen/Octreotide Pamoate vs Tamoxifen/Placebo in Women with Locally Recurrent or Metastatic Breast Cancer (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				SANDOZ-SMST-302 NCI-V96-0934

Last Modified: 11/9/2006


3.		Phase III Study of the Addition of Octreotide Pamoate (SMS 201-995 pa LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Women With Axillary Node Negative, Estrogen Receptor Positive, Primary Invasive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Not specified				NCI				NSABP-B-29 NCT00002967


4.		Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CSMS995ADE05 NCT00171873

Last Modified: 12/1/2000


5.		Phase I Study of Octreotide Pamoate With or Without Tamoxifen in Patients With Osteosarcoma (Summary Last Modified 12/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				25 and under (at time of diagnosis)				NCI				NCI-95-C-0119I NCI-T96-0047N, T96-0047

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute